Invex Therapeutics Ltd
IXC
Company Profile
Business description
Invex Therapeutics Ltd is a biopharmaceutical company focused on repurposing the approved drug Exenatide for the treatment of neurological conditions derived from or involving raised intracranial pressure, including Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. The Group's activities include the research and development of Exenatide, including pre-clinical research in Alzheimer's disease in collaboration with Tessara Therapeutics. It operates in one segment, comprising research and development activities within Australia.
Contact
101 St Georges Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,357.94 | 3.42 | -0.04% |
| DAX 40 | 26,728.04 | 43.84 | -0.16% |
| Dow JONES (US) | 52,297.09 | 189.40 | -0.36% |
| FTSE 100 | 10,873.47 | 10.38 | 0.10% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 25,366.09 | 100.10 | -0.39% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,592.40 | 26.98 | -0.35% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |